Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01401062
Other study ID # S11-00533
Secondary ID BC100481
Status Completed
Phase Phase 2
First received
Last updated
Start date July 2011
Est. completion date June 2014

Study information

Verified date February 2019
Source Weill Medical College of Cornell University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test safety of combining fresolimumab and local radiotherapy and to see if the combination can achieve tumor regression.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date June 2014
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Biopsy-proven breast cancer, metastatic (persistent or recurrent).

- Failed =1 line of therapy (endocrine or chemotherapy) for metastatic disease.

- Min. 3 distinct metastatic sites, at least one measurable lesion which is at least 1 cm or larger in largest diameter.

- Must be =4 weeks since all of the following treatments (recovered from toxicity of prior treatment to =Grade 1, excluding alopecia):

- major surgery;

- radiotherapy;

- chemotherapy (=6 weeks since therapy if a nitrosourea, mitomycin, or monoclonal antibodies such as bevacizumab);

- immunotherapy;

- biotherapy/targeted therapies.

- >18 years of age.

- Life expectancy >6 months.

- Eastern Cooperative Oncology Group (ECOG) status 0 or 1.

- Adequate organ function including:

- Hemoglobin =10.0g/dL, absolute neutrophil count (ANC) =1,500/mm3, and platelets =100,000/mm3.

- Hepatic: Serum total bilirubin =1.5x upper limit of normal (ULN) (Patients with Gilbert's Disease may be included if total bilirubin is =3.0mg/dL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) =2.5xULN. If patient has known liver metastases, ALT and/or AST =5xULN are allowed.

- Renal: creatinine clearance =60mL/min.

- Prothrombin (PT) and partial thromboplastin times (PTT) <ULN.

- Negative for hepatitis viruses B and C unless consistent with prior vaccination or prior infection with full recovery.

- Patients of childbearing potential must agree to use effective contraception while on study, and for =3 months after last treatment.

- Understand and sign written informed consent document. No consent by durable power of attorney.

Exclusion Criteria:

- Second malignancy - unless following curative intent therapy, has been disease free for =2 years with probability of recurrence <5%. Curatively treated early-stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or cervical intraepithelial neoplasia (CIN) are allowed.

- Concurrent cancer therapy.

- Uncontrolled central nervous system (CNS) metastases, meningeal carcinomatosis, malignant seizures, or disease that causes or threatens neurologic compromise (e.g. unstable vertebral metastases).

- History of ascites or pleural effusions, unless successfully treated.

- Organ transplant, including allogeneic bone marrow transplant.

- Immunosuppressive therapy including:

- Systemic corticosteroid therapy, including replacement therapy for hypoadrenalism. Inhaled or topical corticosteroids are allowed (if therapy is <5 days and is limited to systemic steroids as antiemetics);

- Cyclosporine A, tacrolimus, or sirolimus.

- Investigational agents within 4 weeks prior to study enrollment (=6 weeks if treatment was long-acting agent such as monoclonal antibody).

- Significant or uncontrolled medical illness, e.g. congestive heart failure (CHF), myocardial infarction, symptomatic coronary artery disease, significant ventricular arrhythmias within the last 6 months, or significant pulmonary dysfunction. Patients with remote history of asthma or active mild asthma may participate.

- Active infection, including unexplained fever (>38.5°C).

- Systemic autoimmune disease (e.g. systemic lupus erythematosus, active rheumatoid arthritis).

- Known allergy to any component of GC1008.

- Active thrombophlebitis, thromboembolism, hypercoagulability states, bleeding, or anti-coagulation therapy (including anti platelet agents i.e. aspirin, clopidogrel, ticlopidine, dipyridamole, other agents inducing long-acting platelet dysfunction). Patients with history of deep venous thrombosis are allowed if treated, completely resolved, and no treatment for >4months.

- Calcium >11.0mg/dL (2.75mmol/L) unresponsive or uncontrolled in response to standard therapy (e.g. bisphosphonates).

- Patients who, in the opinion of the Investigator, have significant medical or psychosocial problems, including, but not limited to:

- Other serious non-malignancy-associated conditions that may be expected to limit life expectancy or significantly increase the risk of SAEs;

- Conditions, psychiatric, substance abuse, or other, that, in the opinion of the Investigator, would preclude informed consent, consistent follow-up, or compliance with any aspect of the study;

- Pregnant or nursing women.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fresolimumab

Radiation:
Radiation Therapy


Locations

Country Name City State
United States David Geffen School of Medicine at UCLA Los Angeles California
United States New York University Langone Medical Center Cancer Center New York New York

Sponsors (2)

Lead Sponsor Collaborator
Weill Medical College of Cornell University University of California, Los Angeles

Country where clinical trial is conducted

United States, 

References & Publications (1)

Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624. Epub 2009 Nov 24. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Abscopal Response Rate Defined as the percentage of patients who have responses (complete or partial) outside the irradiated lesions. The abscopal response is assessed at 15 weeks, and confirmed minimum 4 weeks later. The abscopal response is evaluated based on immune-related response criteria (irRC) (Wolchok et al, 2009). up to 20 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT04872608 - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Phase 1
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Completed NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer Phase 2
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Recruiting NCT03368729 - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Completed NCT04103853 - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer Phase 1
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Active, not recruiting NCT03147287 - Palbociclib After CDK and Endocrine Therapy (PACE) Phase 2
Not yet recruiting NCT06062498 - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT04095390 - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Phase 2
Active, not recruiting NCT04432454 - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Recruiting NCT05744375 - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Phase 2
Completed NCT02924883 - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy Phase 2
Completed NCT01942135 - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Phase 3
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT01401959 - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Phase 2
Terminated NCT04720664 - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer Phase 2